产品中心 药物靶点和Fc受体 药物靶点

所有图片(1/3)

Osteoprotegerin/TNFRSF11B His Tag Protein, Human

OCIF,OPG

价格 720.00 供应商现货 : 3-5个工作日
货号 UA011378
规格
数量
收藏 分享

产品介绍 评论(0)

产品规格
  • 物种

    Human
  • 分子别名

    OCIF,OPG
  • Accession

    O00300
  • 表达序列

    Glu22-Leu401 with His Tag at the C-Terminus

  • 表达宿主

    HEK293
  • 分子量

    50-60kDa (Reducing)

  • 纯度

    >95% by SDS-PAGE
  • 活性

    Immobilized Osteoprotegerin/TNFRSF11B His Tag Protein, Human (Cat. No. UA011378) at 2.0μg/mL (100μL/well) can bind TRAIL/Apo2L Protein, Human (Cat. No. UA040039) with EC50 of 2.41-3.28 ng/mL.Immobilized TRAIL/Apo2L Protein, Human (Cat. No. UA040039) at 2.0μg/mL (100μL/well) can bind Osteoprotegerin/TNFRSF11B His Tag Protein, Human (Cat. No. UA011378) with EC50 of 6.94-10.74 ng/mL.
  • 标记

    Unconjugated
  • 标签

    His Tag
  • 性状

    Lyophilized Powder
  • 缓冲体系

    PBS, PH7.4, 5% trehalose

  • 溶解方法

    Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.

  • 储存条件

    · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
    · 3 months, -20 to -80℃ under sterile conditions after reconstitution.
    · 1 week, 2 to 8℃ under sterile conditions after reconstitution.
    · Please avoid repeated freeze-thaw cycles.

  • 文献引用

    Shin SY, Kang IS, Kim C. ERK inhibits osteoclast differentiation in RAW 264.7 cells through the osteoprotegerin-mediated autophagy. Bone. 2025 Apr;193:117424.
    2.Radhi JH, El-Hagrasy AMA, Almosawi SH, Alhashel A, Butler AE. The Role of Osteoprotegerin in Breast Cancer: Genetic Variations, Tumorigenic Pathways, and Therapeutic Potential. Cancers (Basel). 2025 Jan 21;17(3):337.

背景介绍
  • Osteoprotegerin (OPG/TNFRSF11B/OCIF) is a member of the tumor necrosis factor receptor superfamily, secreted by osteoblasts as a homodimeric protein.Its core function is as a decoy receptor: 1) By binding with high affinity to RANKL, it competitively blocks RANKL from activating its functional receptor RANK, thereby strongly inhibiting osteoclast differentiation and activation while promoting their apoptosis, making it a key negative regulator of bone resorption. 2) It can also bind to TRAIL (TNFSF10), exerting an anti-apoptotic effect.Bone homeostasis directly depends on the local RANKL/OPG concentration ratio.As a central molecule in maintaining bone metabolic balance, abnormalities in its mechanism are closely associated with osteoporosis. Furthermore, studies suggest it plays important roles in regulating lymph node development and preventing vascular calcification, while its interaction with TRAIL may have implications in oncology and other fields.

  • 电泳

    • 1μg (R: reducing condition, N: non-reducing condition).

  • ELISA

    • Immobilized Osteoprotegerin/TNFRSF11B His Tag Protein, Human (Cat. No. UA011378) at 2.0μg/mL (100μL/well) can bind TRAIL/Apo2L Protein, Human (Cat. No. UA040039) with EC50 of 2.41-3.28 ng/mL.

    • Immobilized TRAIL/Apo2L Protein, Human (Cat. No. UA040039) at 2.0μg/mL (100μL/well) can bind Osteoprotegerin/TNFRSF11B His Tag Protein, Human (Cat. No. UA011378) with EC50 of 6.94-10.74 ng/mL.

评论(0)